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The concept of intramembrane proteases 
(I-CLIPs) cleaving within the phospholipid 
bilayer was initially put forward based on process-
ing of the sterol regulatory element–binding 
protein (SREBP; Brown and Goldstein, 1997; 
Wolfe and Kopan, 2004). Usually, I-CLIPs op-
erate as part of a proteolytic sequence referred 
to as regulated intramembrane proteolysis (RIP; 
Lichtenthaler et al., 2011). Intracellular domains 
(ICDs) of several RIP substrates function as sig-
naling molecules after their proteolytic release as 
exemplified by the Notch pathway (De Strooper 
et al., 1999; Urban and Freeman, 2002). Based 
on their catalytic center, serine, metallo, or aspar-
tyl I-CLIPs (Wolfe, 2009) can be differentiated. 
The group of aspartyl I-CLIPs comprises the pre-
senilins being part of the -secretase complex and 
the SPP/SPPL (signal-peptide-peptidase[-like]) 
family, with apparent specificity for transmem-
brane proteins in type 1 and type 2 orientation, 
respectively (Wolfe and Kopan, 2004).
Among the SPPLs, SPPL2a appears to be 
unique in its residence in lysosomes/late endo-
somes (Behnke et al., 2011). To date, only TNF 
(Friedmann et al., 2006; Fluhrer et al., 2006), 
Fas ligand (Kirkin et al., 2007), and Bri2 (Martin 
et al., 2008) have been identified as SPPL2a sub-
strates by in vitro studies. In DCs, RIP of TNF 
has been shown to influence expression of the 
proinflammatory cytokine IL-12 (Friedmann 
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Regulated intramembrane proteolysis is a central cellular process involved in signal  
transduction and membrane protein turnover. The presenilin homologue signal- 
peptide-peptidase-like 2a (SPPL2a) has been implicated in the cleavage of type 2 transmem-
brane proteins. We show that the invariant chain (li, CD74) of the major histocompatability 
class II complex (MHCII) undergoes intramembrane proteolysis mediated by SPPL2a.  
B lymphocytes of SPPL2a/ mice accumulate an N-terminal fragment (NTF) of CD74, which  
severely impairs membrane traffic within the endocytic system and leads to an altered 
response to B cell receptor stimulation, reduced BAFF-R surface expression, and accumula-
tion of MHCII in transitional developmental stage T1 B cells. This results in significant loss 
of B cell subsets beyond the T1 stage and disrupted humoral immune responses, which can 
be recovered by additional ablation of CD74. Hence, we provide evidence that regulation of 
CD74-NTF levels by SPPL2a is indispensable for B cell development and function by main-
taining trafficking and integrity of MHCII-containing endosomes, highlighting SPPL2a as a 
promising pharmacological target for depleting and/or modulating B cells.
© 2013 Schneppenheim et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first 
six months after the publication date (see http://www.rupress.org/terms). After 
six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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significant amounts of CD74 NTF due to impaired turnover 
by RIP, and show arrested B cell development at the T1 stage, 
in addition to functional defects of the residual B cells. How-
ever, this phenotype was significantly alleviated in SPPL2a-
CD74 double-deficient mice. Therefore, we propose that the 
primary purpose of CD74 intramembrane cleavage mediated 
by SPPL2a is to tightly control the level of the CD74 NTF. 
We demonstrate that this NTF is capable of perturbing mem-
brane traffic in the endocytic system documented by the ac-
cumulation of endosomal vacuoles in SPPL2a/ B cells and 
secondarily interferes with cellular signaling pathways critical 
for developing B cells exemplified by reduced surface expres-
sion levels of the BAFF receptor (BAFF-R) and B cell anti-
gen receptor (BCR) induced Ca2+ mobilization. Hence, we 
have identified a novel molecular mechanism mediating tight 
control of CD74 NTF levels, a process that is indispensable 
for cellular homeostasis of B cells. Based on this, pharmaco-
logical inhibition of SPPL2a may represent a novel therapeu-
tic strategy for depleting B cells.
RESULTS
SPPL2a is the postulated intramembrane  
protease cleaving CD74
We evaluated the CD74 NTF, which, after removal of the 
CLIP segment by cathepsin S (Fig. 1 A), remains as a novel 
substrate of the poorly characterized intramembrane prote-
ase SPPL2a. We applied (Z-LL)2-ketone or the inhibitor X 
(L-685,458), which are established SPP/SPPL inhibitors 
(Weihofen et al., 2003; Friedmann et al., 2006), to HEK293 
cells stably overexpressing epitope-tagged murine CD74 
(Fig. 1 B). The inhibitor treatment induced stabilization of a 
CD74 NTF that was distinctly smaller than those CD74 deg-
radation intermediates detected after inhibition of cysteine 
proteases by leupeptin (Fig. 1 B; Matza et al., 2003). When ly-
sosomal acidification was impaired by NH4Cl, accumulation 
of full-length CD74 was induced. In a more specific approach, 
we performed siRNA-mediated knockdown of SPPL2a in 
CD74-expressing HEK293 cells (Fig. 1 C). This increased the 
amount of CD74 NTF in a manner similar to the inhibitor 
treatment. In steady state, only low levels of this CD74 NTF 
were detectable (Fig. 1 B), presumably because of rapid turn-
over by endogenous SPPL2a. However, the steady-state level 
of CD74 NTF in transfected HEK293 cells could be even 
further reduced by co-expressing CD74 and SPPL2a (Fig. 1 D). 
This was not observed with the catalytically inactive SPPL2a-
D416A variant. Collectively, these different experimental ap-
proaches strongly indicated that SPPL2a is responsible for the 
turnover of CD74 NTF.
B cells of SPPL2a/ mice accumulate CD74 NTF
To confirm the role of SPPL2a for RIP of CD74 in vivo and 
to scrutinize the physiological relevance of this process, we 
generated SPPL2a-deficient mice (Fig. 2 A), which were via-
ble, fertile, and without any overt impairment. We specifically 
analyzed the processing of endogenous CD74 in SPPL2a/-
purified IgM+ splenic B cells (Fig. 1 E). Although CD74 NTF 
et al., 2006). Beyond that, the physiological significance of 
SPPL2a-mediated RIP is unknown.
Based on its presence in late endocytic compartments and 
the specificity for type 2 membrane proteins, we searched for 
novel substrates of SPPL2a and investigated the invariant 
chain (li, CD74) as a candidate. This protein has been exten-
sively studied as a chaperone of MHC class II complexes 
(MHCII), which present antigens to CD4+ helper T cells in 
a key process of adaptive immunity (Neefjes et al., 2011). In 
antigen-presenting cells, the type 2 transmembrane protein 
CD74 binds the newly assembled MHCII dimers in the ER, 
thereby preventing premature peptide binding, and directs 
the nonameric 33li3 complex to specialized endosomes re-
ferred to as MHCII compartments. There, MHCII is loaded 
with antigen-derived peptides, after the luminal domain of 
CD74 has been removed by sequential proteolytic degrada-
tion (Matza et al., 2003).
Consistently, absence of CD74 in mice disrupts matura-
tion of MHCII, antigen presentation and development of 
CD4+ T cells (Bikoff et al., 1993). However, CD74-deficient 
mice also show compromised B cell maturation beyond the 
transitional developmental stages, leading to impaired hu-
moral immune responses (Shachar and Flavell, 1996). Trun-
cated N-terminal fragments (NTFs) of CD74 that are devoid 
of the MHCII binding CLIP (class II–associated li chain 
peptide) segment were reported to rescue maturation of 
B cells in these mice (Matza et al., 2002b). Based on this 
observation, an intrinsic and MHCII-independent role of 
CD74 by providing specific signals for B cell maturation 
was suggested. According to this concept, release of the intra-
cellular domain (ICD) of CD74 by a yet unknown intra-
membrane protease from the membrane-bound N-terminal 
CD74 fragment (NTF) is required for transducing these 
maturation signals (Matza et al., 2002a; Becker-Herman 
et al., 2005). Downstream effects of this process were shown 
to be diverse (Starlets et al., 2006; Lantner et al., 2007), 
including activation of the NF-B pathway (Matza et al., 
2002a), and dependent on the transcription factor TAFII105 
(Matza et al., 2001). However, the molecular details of the 
intramembrane cleavage of CD74 and ICD-mediated sig-
naling remain unclear to date. Furthermore, this concept 
has been challenged by the observation that additional abla-
tion of all MHCII subunits (Madsen et al., 1999) was able 
to completely restore the B cell deficiency of CD74/ 
mice (Maehr et al., 2004). In contrast to the model dis-
cussed above, these findings clearly indicated that the mech-
anisms leading to the B cell maturation defect in the absence 
of CD74 involve and depend on MHCII. In addition, nei-
ther CD74 nor MHCII appear to be absolutely essential in 
developing B cells because B cell maturation was apparently 
not impaired in CD74-MHCII double-deficient mice 
(Maehr et al., 2004).
In this study, we present evidence in vitro and in vivo that 
SPPL2a is the postulated I-CLIP of CD74, and we also clarify 
the significance of this proteolytic event for B cell develop-
ment and homeostasis. SPPL2a-deficient mice accumulate 
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SPPL2a/ mice fail to perform RIP of CD74. Similar 
results were obtained for other CD74-expressing cell types, 
such as BM-derived DCs (BMDCs) and splenic CD11c+ 
DCs (unpublished data).
was hardly detectable in wild-type B cells, SPPL2a-deficient 
B cells exhibited large amounts of accumulating NTF, 
demonstrating that in vivo active SPPL2a is also required for 
complete degradation of  CD74 and that B cells from 
Figure 1. The intramembrane protease SPPL2a cleaves CD74 NTF. (A) Scheme of proteolytic degradation of CD74 in MHCII compartments, where 
the luminal domain is removed in a stepwise fashion by endosomal proteases and finally released from the MHCII dimer by cathepsin S. A small fragment 
(CLIP) persists inside the peptide-binding groove of MHCII, which is subsequently replaced with an antigenic peptide before the MHCII–peptide complex is 
transported to the plasma membrane. The remaining transmembrane NTF (82 aa) of CD74 is then proteolyzed by SPPL2a. The catalytically critical YD and 
GxGD motifs of SPPL2a are indicated by colored asterisks. (B) HEK293 cells stably expressing the p31 isoform of CD74 (HA-CD74p31-V5) were treated 
with 10 µM (Z-LL)2-ketone, 1 µM inhibitor X, 100 µM leupeptin or 25 mM NH4Cl for 5 h. The CD74 NTF is indicated by the open arrowheads. Full-length 
CD74 (closed arrowheads) and CD74 NTF were detected with anti-HA recognizing the epitope tag fused to the N terminus of the protein. (C) Transient 
knockdown of SPPL2a in HEK293 cells stably expressing HA-tagged CD74 (HA-CD74p31-V5). SPPL2a and the lysosomal membrane protein LAMP2 as 
control were analyzed in carbonate-washed membranes from the same batch of cells for enhancing SPPL2a detectability. (D) SPPL2a or the inactive 
D416A mutant were transiently co-expressed with CD74, followed by detection with anti-CD74 (In-1). (E) Using an antibody against an N-terminal epitope 
of CD74, endogenous CD74 was analyzed in splenic IgM+ B cells isolated from SPPL2a/ and control mice. (B–E) Electrophoretic separation before  
detection of CD74 was performed by standard Tris-Glycine SDS-PAGE (D) or using a Tris-Tricine buffer system (B, C, and E) with improved resolution in 
the low-molecular weight range. Equal protein loading was confirmed as indicated. Data are representative of three independent experiments.
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Figure 2. SPPL2a deficiency leads to impaired B cell development and function. (A) Generation of SPPL2a-deficient mice. The exon–intron struc-
ture of the murine SPPL2a gene, layout of the targeting construct, and structure of the targeted locus are depicted. Positions of primers and probes used 
for genotyping by PCR and Southern blot, respectively, are indicated. Genotyping of SPPL2a/ mice was performed by PCR. DNA isolated from SPPL2a+/+ 
and SPPL2a/ tail biopsies was amplified with either gene-specific (SPPL2a) or neomycin-specific primers. Total RNA was isolated from SPPL2a+/+ and 
SPPL2a/ murine embryonic fibroblasts. After reverse transcription, primers annealing in exon 1 and exon 3 of the SPPL2a ORF as indicated were used to 
amplify a 342-bp fragment of the SPPL2a wild-type ORF from the cDNA. In parallel, appropriate primers for a fragment of -actin were used as control. 
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[PI] cells), LNs (18 vs. 54.4% of PI cells), and the peri-
toneal cavity (11.4 vs. 49.2% of PI cells) in comparison to 
control mice. A decrease was detected for all mature B cell 
subsets, including marginal zone B cells and B1 B cells 
(Tables 1 and 2). In addition, at the sites of B cell differ-
entiation, bone marrow, and spleen, a significant, though 
slightly less pronounced, decrease was observed (Fig. 2 B). 
SPPL2a/ mice show impaired B cell development
To assess the influence of reduced CD74 RIP on B cell 
development, we quantified B cells in different lymphatic 
tissues of SPPL2a/ mice by flow cytometry (Fig. 2 B 
and Tables 1 and 2).  Intriguingly, the amount of B cells 
(B220+) was significantly reduced in blood of SPPL2a/ 
mice (7.6 vs. 24.6% of viable, propidium iodide–negative 
Table 1. Immune cells in different lymphatic tissues and peritoneal cells of wild-type and SPPL2a-deficient mice
Cell type SPPL2a+/+ SPPL2a/ P-value
 Mean  SD  Mean SD 
BM
 B cells B220+ 21.4 6.1 15.3 2.5 0.031*
 T cells CD3+ 1.8 1.2 1.1 1 0.066
 Mature granulocytes CD11b+ Gr1high 63.4 9.6 70.5 1.4 0.137
 Immature granulocytes CD11b Gr1+ 8.1 2.6 7.8 3.2 0.623
 DCs CD11c+ 2.9 2.5 2.8 2 0.714
 NK cells CD49b+ 2.6 0.6 2.1 0.7 0.078
Spleen
 B cells B220+ 45.6 6.6 23.9 13.1 <0.001***
 Follicular B cells B220+ CD21+ CD23+ 29.5 8.5 8.7 4.1 0.023*
 Marginal zone B220+ CD21+ CD23/low 4.6 1.6 1.3 0.2 0.026*
 T cells CD3+ 32.7 4.4 38.3 3.6 0.01*
LNs
 B cells B220+ 54.4 5 18 12.3 <0.001***
 T cells CD3+ 35.7 4.2 59.5 11.4 0.018*
 Macrophages F4/80+ 4.8 3.6 3.6 1.3 0.12
 DCs CD11c+ 0.5 0.2 0.7 0.7 0.872
Blood
 B cells B220+ 24.6 4.2 7.6 1.9 <0.001***
Peritoneal cells
 B cells B220+ 49.2 10.8 11.4 5 <0.001***
 Mast cells Ckithigh ST2high 1.8 0.8 3.8 2.2 0.061
Thymus
 Double-positive T cells CD4+ CD8+ 78.8 4.3 81.5 5.7 0.289
 CD4+ T cells CD4+ CD8 13.7 2.8 11.5 3.6 0.193
 CD8+ T cells CD4 CD8+ 3.4 1.2 3.1 1.4 0.582
 Double-negative T cells CD4 CD8 4.2 1.2 3.8 1.4 0.54
Cells from six mice of each genotype were analyzed by flow cytometry to determine the proportions of the indicated cell populations, which are shown as the percentage of 
viable cells (PI). Results are listed as mean ± SD. ***, P < 0.001; *, P < 0.05, unpaired Student’s t test.
(B) The frequency of B cells (B220+, % of PI cells) in BM, spleen, blood, LNs, and the peritoneal cavity (PC) of SPPL2a/ compared with SPPL2a+/+ mice. 
Mean ± SD; n = 6–12. ***, P < 0.001; *, P < 0.05, unpaired, two-tailed Student’s t test. (C) Representative sections of Peyer’s patches from SPPL2a+/+ and 
SPPL2a/ mice were stained with hematoxylin and eosin or used for immunohistochemical visualization of B220+ B cells. Bars, 500 µm. (D) Mean num-
ber and diameter of Peyer’s patches in small intestines of SPPL2a+/+ and SPPL2a/ mice were determined by macroscopic inspection or measurement 
using a stereomicroscope, respectively. Mean ± SD; n = 9. ***, P < 0.001, unpaired, two-tailed Student’s t test. (E) Regular splenic architecture and segre-
gation of B (B220, brown) and T (CD3, blue) cells in SPPL2a/ mice. Bars, 500 µm. (F–H) Frequencies of pre–/pro–, immature (I), and recirculating mature 
B cells (M) in the BM and transitional stage T1 and T2 and mature B cells (M) in spleens of SPPL2a+/+ and SPPL2a/ mice were determined by co-staining 
of B220 together with IgM or CD21 and CD24, respectively, and are shown as percentage of viable cells from a representative experiment (F, numbers 
indicate percentage of viable cells) or as mean ± SD; n = 7 (G; BM) or n = 9 (H; spleen). ***, P < 0.001; **, P < 0.01; *, P < 0.05, unpaired, two-tailed Stu-
dent’s t test. (I) The expression level of SPPL2a was determined in FACS-sorted splenic B cell subsets (transitional stage T1 and T2, mature B cells) from 
wild-type mice by Western blotting. Actin levels were used for normalization. To control specificity of the SPPL2a antibody, splenocyte lysates isolated 
from wild-type and SPPL2a-deficient mice were included. One of two independent experiments is shown.
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B cell maturation pathways and B cell function  
are impaired in SPPL2a/ mice
To rule out a role of SPPL2a in stromal cells during B cell 
development, BM from SPPL2a/ mice and SPPL2a+/+ 
controls was transplanted into immunodeficient Rag2/ 
cc/ mice (Fig. 3 A and Table 3).  Recipients of SPPL2a/ 
BM developed a B cell phenotype characterized by a signifi-
cant decrease in splenic transitional T2 cells and mature B cells 
in the spleen and BM, reminiscent of the findings from 
SPPL2a/ mice. Evidently, the B cell maturation defect of 
SPPL2a/ mice was passed on to host animals by hemato-
poietic stem cells, strongly suggesting a cell-intrinsic defect.
Two pathways are of especially critical importance for 
promoting further maturation of splenic transitional stage T1 
B cells: signals provided by the BCR and by the cytokine 
BAFF and its three different receptors BAFF-R, TACI, and 
BCMA (Khan, 2009). We analyzed putative alterations of 
these pathways that may contribute to the observed devel-
opmental block of SPPL2a-deficient B cells at the T1 stage. 
Because BAFF signals on transitional B cells are mainly 
transduced by the BAFF-R (Shulga-Morskaya et al., 2004), 
we examined the surface expression of BAFF-R on SPPL2a/ 
T1 B cells in comparison to wild-type T1 cells and ob-
served a significant reduction on the SPPL2a-deficient cells 
(Fig. 3 B), suggesting that BAFF-encoded survival signals 
may not be adequately received by those cells. Furthermore, 
we determined the response to BCR stimulation monitored 
by cytosolic Ca2+ mobilization. In SPPL2a/ T1 B cells, 
especially the Ca2+ entry across the plasma membrane was 
The B cell deficiency was reflected in reduced spleen size 
(70% of wild-type) and atrophic Peyer’s patches (Fig. 2, C 
and D). However, the general morphology of spleen (Fig. 2 E) 
and LNs (not depicted), as well as the segregation of B and 
T cells into their respective zones, were found to be preserved. 
Furthermore, populations of other immune cells were not 
quantitatively changed in SPPL2a/ mice (Table 1).
The frequency of pre- and intermediate stages of B cells 
in the BM of SPPL2a/ mice was unchanged up to the im-
mature B cell stage (Fig. 2, F and G, and Table 2). Whereas 
abundance of transitional T1 cells was not significantly 
changed in spleens of SPPL2a-deficient (8.2% of PI cells, 
1.8 × 106 splenocytes) versus wild-type mice (7.5% of PI cells, 
5.2 × 106 splenocytes), T2 (0.5 vs. 11.2% of PI cells, 0.1 vs. 
7.9 × 106 splenocytes) and mature B cells (7.0 vs. 23.9% of 
PI cells, 1.8 vs. 17.8 × 106 splenocytes) were severely re-
duced (Fig. 2, F and H, and Table 2) demonstrating that the 
decrease in B cells becomes apparent after the T1 stage.
Based on the observed B cell maturation block at the 
T1 stage in SPPL2a/ mice, we aimed to confirm expression 
of SPPL2a in the respective B cell subsets. We investigated puta-
tive differences in SPPL2a abundance by Western blot analysis 
of FACS-sorted splenic T1, T2, and mature B cells. SPPL2a 
was detected in all three populations (Fig. 2 I). However, den-
sitometric quantification and normalization to actin indicated 
a threefold higher expression of this protease in transitional 
stage 1 as compared with T2 or mature B cells in two inde-
pendent experiments. We therefore considered a crucial role 
of SPPL2a in transitional stage 1 B cells.
Table 2. B cell subsets in different lymphatic tissues, blood and peritoneal cells of wild-type and SPPL2a-deficient mice
Cell type  SPPL2a+/+ SPPL2a/  P-value
  Mean  SD  Mean  SD  
BM (% of viable cells)
 B cells B220+ 21.4 6.1 15.3 2.5 0.031*
 Pro– /pre–B cells B220+ IgM 8.5 1.9 10.3 2 0.099
 Immature B cells B220+ IgM+ 3.6 1.9 4.1 2.3 0.694
 Recirculating B cells B220high 8.6 3.6 0.7 0.2 <0.001***
Spleen (% of viable cells)
 B cells B220+ 45.6 6.6 23.9 13.1 <0.001***
 T1 transitional B220+ CD21low CD24high 7.5 0.7 8.2 4.9 0.785
 T2 transitional B220+ CD21high CD24high 11.2 3.1 0.5 0.6 <0.001***
 Mature B cells B220+ CD21low CD24low 23.9 7.1 7.0 4.4 0.007**
Spleen (×106 splenocytes)
 B cells B220+ 33.3 13.5 4.2 2.2 0.021*
 T1 transitional B220+ CD21low CD24high 5.2 2.3 1.8 0.6 0.056
 T2 transitional B220+ CD21high CD24high 7.9 2.9 0.1 0.1 0.013*
 Mature B cells B220+ CD21low CD24low 17.8 7.3 1.8 1.2 0.021*
Peritoneal cells (% of viable cells)
 B cells B220+ CD19+ 49.2 10.8 11.4 5.0 <0.001***
 B1 B220neg/low CD19high 34.2 13.8 6.7 4.7 <0.001***
 B2 B220high CD19+/low 15.1 6.9 2.1 1.7 0.001**
Cells of each genotype were analyzed by flow cytometry to determine the indicated cell populations as percentage of viable cells (PI) or absolute cell numbers, respectively. 
BM, n = 7; spleen, n = 9; blood, n = 6; LNs n = 5; peritoneal cells, n = 12. Results are shown as mean ± SD. ***, P < 0.01; **, P < 0.01; *, P < 0.05, unpaired Student’s t test.
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Figure 3. B cell maturation pathways and B cell function are impaired in SPPL2a/ mice. (A) BM from either wild-type or SPPL2a-deficient mice was 
transplanted into irradiated Rag2/ cc/ mice. After 10 wk, B cell subsets in BM and spleen were analyzed by co-staining of B220 together with IgM or CD21 
and CD24, respectively, and quantified as percentage of viable cells (numbers). Data shown are representative of eight experiments (Table 3). (B) B220+ cells were 
isolated from spleens of SPPL2a+/+ and SPPL2a/ mice and stained for CD21, CD24, and BAFF-R. Histograms show the BAFF-R expression on SPPL2a+/+ (solid 
line, black) and SPPL2a/ (solid line, red) T1 B cells (B220+ CD21low CD24high) from a representative of three independent experiments. Specificity of the BAFF-R 
staining was confirmed by the respective isotype controls (dashed lines). (C) Splenocytes from SPPL2a/ and wild-type mice were stained for B220, CD21, and 
CD24 and loaded with the ratiometric Ca2+-sensitive fluorophore Indo-1-AM. After monitoring of basal Ca2+ concentrations in T1 B cells (B220+ CD21low CD24high) 
for 30 s, cells were stimulated with goat anti–mouse IgM F(ab’)2 fragments and Ca2+ flux was recorded for 5 min in the absence of extracellular Ca2+ and for an 
additional 5 min in the presence of 1 mM extracellular CaCl2. Data are representative of three experiments and were also confirmed in repopulated RAG/cc/ 
mice (not depicted). (D) Plasma immunoglobulin levels were measured in wild-type (wt) and SPPL2a/ mice (ko). Mean ± SD; n = 8–12. ***, P < 0.001; **, P < 0.01;  
*, P < 0.05, unpaired, two-tailed Student’s t test. (E and F) SPPL2a/ (ko) and wild-type mice (wt) were immunized with the T cell–independent or –dependent 
antigens TNP-Ficoll (E) or TNP-KLH (F), respectively. Hapten-specific immunoglobulin levels were determined 14 d after antigen application (E and F). For  
TNP-KLH (F), antigen application was repeated at day 14 and additional serum samples were obtained after an additional 2 wk, at day 28. Results are depicted as 
mean ± SD; n = 6 per genotype and experimental group, ***, P < 0.001; **, P < 0.01; *, P < 0.05, unpaired, two-tailed Student’s t test.
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unstable cleavage product (ICD) that is released into the 
cytosol will be abolished in SPPL2a/ B cells, and signals 
putatively transduced by this molecule will be reduced. At the 
same time, the CD74 NTF, which is meant to be cleaved by 
SPPL2a, is accumulating in these cells because of failed turn-
over at apparently nonphysiological levels (see also Fig. 1 E), 
and this may perturb cellular processes and homeostasis. If 
absence of the CD74 ICD were the main mechanism for the 
observed B cell phenotype in SPPL2a/ mice, as well as in 
CD74/ mice, one would expect highly similar B cell phe-
notypes in both mice. However, we were intrigued by dis-
tinct differences. B cell reduction and functional impairment 
caused by deficiency of SPPL2a appeared to be significantly 
more severe than by absence of CD74 (Shachar and Flavell, 
1996; Maehr et al., 2004). Furthermore, the developmental 
arrest becomes apparent at an earlier stage, as CD74/ mice 
were reported to possess normal amounts of transitional stage 
T2 cells (Maehr et al., 2004), which are already significantly 
reduced in SPPL2a/ mice.
We considered a causative role of the accumulating NTF 
in the evolution of the B cell defect and analyzed its subcellu-
lar localization using an antibody detecting full-length CD74, 
as well as NTF (Fig. 4, A and B). According to our aforemen-
tioned results, the obtained signals in SPPL2a/ B cells 
should primarily represent distribution of the NTF and were 
detected in prominent vesicular structures positive for the 
early endosome antigen 1 (EEA1) and LAMP1, which are 
markers of early endosomes and lysosomes/late endosomes, 
decreased in comparison to wild-type cells (Fig. 3 C). In sum-
mary, absence of SPPL2a interferes with two central pathways 
involved in promoting B cell maturation.
To assess the functional competence of the residual B cells, 
we determined basal immunoglobulin levels in SPPL2a-
deficient and wild-type mice (Fig. 3 D) and performed immu-
nization with T cell–independent (Fig. 3 E) and –dependent 
(Fig. 3 F) model antigens. Basal immunoglobulin levels were 
significantly reduced throughout all subclasses in SPPL2a-
deficient mice as compared with controls. The antibody re-
sponse to the T cell–independent antigen trinitrophenol 
(TNP)-Ficoll was severely impaired in SPPL2a/ mice, 
which was shown by only marginal amounts of TNP-specific 
immunoglobulin being detectable in the sera of these mice 
(Fig. 3 E). After repeated application of TNP-keyhole limpet 
hemocyanin (KLH) at day 28, TNP-specific IgM reached 
50% of wild-type level in SPPL2a/ mice (Fig. 3 F). Apart 
from that, only marginal amounts of TNP-specific immuno-
globulins were generated by these mice, indicating a sig-
nificant functional impairment of the remaining B cells in 
SPPL2a-deficient mice.
SPPL2a/ B cells accumulate endosomal  
vacuoles containing CD74 NTF
Thinking of a molecular link between CD74 as a substrate of 
SPPL2a on the one hand and as the arrest of B cell develop-
ment in the absence of this protease on the other, two gen-
eral mechanisms are conceivable. First, generation of the final 
Table 3. B cell populations in RAG2/cc/ mice 10 wk after transplantation with BM from SPPL2a+/+ or SPPL2a/ mice
Cell type SPPL2a+/+  SPPL2a/  P-value
   Mean SD Mean SD   
BM (% of viable cells)
B cells B220+ 11.8 3.3 10.9 5.3 0.694
 Pro– /pre–B cells B220+ IgM− 6.2 0.6 7.7 2.5 0.136
 Immature B cells B220+ IgM+ 6.0 1.9 5.1 1.8 0.362
 Recirculating B cells B220high 2.6 1.3 0.3 0.1 <0.001***
Spleen (% of viable cells)
  B cells B220+ 41.6 1.3 20.8 6.9 <0.001***
 T1 transitional B220+ CD21low CD24high 6.4 1.7 11.1 3.8 0.018*
 T2 transitional B220+ CD21high CD24high 2.9 0.3 0.2 0.1 <0.001***
 Mature B cells B220+ CD21low CD24low 24.2 3.6 3.2 2.0 <0.001***
 T helper cells CD3+ CD4+ 10.0 2.4 14.9 3.5 0.038*
 Cytotoxic T cells CD3+ CD8+ 2.5 0.5 6.0 2.7 0.004**
Spleen (x106 splenocytes)
 B cells B220+ 42.5 7.9 11.3 5.2 <0.001***
 T1 transitional B220+ CD21low CD24high 7.3 1.5 5.7 2.4 0.300
 T2 transitional B220+ CD21high CD24high 3.0 0.2 0.1 0.1 <0.001***
 Mature B cells B220+ CD21low CD24low 22.7 4.2 1.9 1.5 <0.001***
 T helper cells CD3+ CD4+ 9.6 2.7 7.8 3.3 0.194
 Cytotoxic T cells CD3+ CD8+ 2.4 0.5 2.8 1.3 0.671
BM from SPPL2a+/+ (n = 8) or SPPL2a/ (n = 8) mice was transplanted into irradiated RAG2/cc/ mice. Cells from BM and spleen of host mice were analyzed 10 wk after 
the transplantation by flow cytometry. Cell populations are expressed as percentage of viable cells (PI, derived from n = 8) or absolute cell numbers (derived from n = 5), 
respectively. Data are listed as mean ± SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05, unpaired Student’s t test.
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SPPL2a-deficient B cells. As CD74 has been implicated in the 
regulation of endosome maturation (Lagaudrière-Gesbert et al., 
2002; Nordeng et al., 2002; Gregers et al., 2003; Landsverk 
et al., 2009, 2011) and the observed vacuoles contain CD74 
NTF, a causal connection between the NTF accumulation 
and the morphological changes is strongly suggested.
We assessed whether the disturbed endosomal membrane 
traffic has any consequences for MHCII homeostasis by flow 
cytometric analysis of total and surface MHCII expression in 
splenic SPPL2a-deficient B cells (Fig. 4, F and G). Through-
out all developmental stages analyzed (T1, T2, and mature 
B cells), SPPL2a/ B cells exhibited significantly increased 
MHCII levels at the cell surface, which was even more pro-
nounced in total after permeabilization. This was also ob-
served by Western blotting (Fig. 1 E).
Changes in ultrastructure and signaling in SPPL2a/ B cells 
are secondary to CD74 NTF accumulation
Following the hypothesis that the CD74 NTF accumulation 
rather than the missing ICD directly or indirectly causes the 
respectively. Apparently, the compartments where CD74 NTF 
accumulates in SPPL2a-deficient B cells are derived from the 
endocytic pathway, which is in agreement with the general 
concept of MHCII trafficking and degradation of CD74 by 
endosomal/lysosomal proteases.
To assess any major structural alterations of the B cells in-
duced by the persistence of the CD74 NTF, we examined 
IgM+ splenic SPPL2a/ B cells by transmission electron micros-
copy. In these cells, we observed abundant vacuoles that were 
not detectable at this frequency in wild-type B cells (Fig. 4 C). 
Many of them exhibited either amorphous, weakly electron-
dense luminal contents or intraluminal vesicles and only 
rarely lamellar structures (Fig. 4 D). Immunogold labeling 
was used to confirm that these conspicuous vacuoles con-
tain CD74 (Fig. 4 E), as well as the lysosomal/late endosomal 
marker protein LAMP1 (Fig. 4 E) and MHCII (Fig. 4 E), 
demonstrating that they are the ultrastructural correlate of 
the prominent CD74-positive vesicles visualized by immuno-
fluorescence. In conclusion, membrane trafficking within 
the endocytic system seems to be significantly disturbed in 
Figure 4. Disturbance of membrane 
traffic within the endocytic system of 
SPPL2a/ B cells. (A and B) Visualization 
of CD74 in isolated splenic SPPL2a+/+ and 
SPPL2a/ B cells by indirect immunofluor-
escence using an antibody against an  
N-terminal epitope detecting the NTF and the 
full-length protein. EEA1 (A) and LAMP1  
(B) served as markers of early endosomes and 
lysosomes/late endosomes, respectively. 
Bars, 2 µm. (C) Transmission electron micros-
copy of splenic IgM+ B cells from wild-type 
or SPPL2a/ mice. Bars, 1 µm. (D) Vacuoles 
in SPPL2a/ B cells exhibited various con-
tents of low-electron density. Occasionally, 
multivesicular bodies (mvb) were observed 
(arrow). Bar, 500 nm. (E) Presence of CD74 
NTF, LAMP1, and MHCII in vacuoles of IgM+ 
B cells from SPPL2a/ mice was assessed by 
immunogold labeling. Bars, 200 nm (CD74 
and MHCII single labeling) or 100 nm (CD74 + 
LAMP1 double labeling). (F and G) Surface 
and total MHCII levels in transitional stage 
T1 B cells (B220+ CD21low CD24high) of SPPL2a-
deficient or wild-type mice. Splenocytes 
were stained for B220, CD21, and CD24, 
allowing for identification of B cell subsets. 
Subsequently, cells were incubated with 
anti-MHCII with or without previous per-
meabilization and analyzed by flow cytom-
etry. Surface and total MHCII levels are 
shown as histograms representative of three 
independent experiments or as mean of me-
dian fluorescence intensity (MFI) from three 
mice per genotype (G). ***, P < 0.001; **, P < 
0.01; *, P < 0.05, unpaired, two-tailed Stu-
dent’s t test.
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exhibited significantly increased total B cells in LNs (12.4 vs. 
3.1% of PI cells) and the peritoneal cavity (38 vs. 8.5% of 
PI cells) as compared with SPPL2a/ mice (Fig. 6, A and B, 
and Table 4). In the spleen, transitional stage T2 B cells (7.9 vs. 
0.5% of PI cells, 2.6 vs. 0.03 × 106 splenocytes) were present 
in significantly higher amounts in the double-deficient ani-
mals (Fig. 6, C–E, and Table 4) as compared with SPPL2a-
deficient mice.  However, because CD74 deficiency itself is 
associated with a reduction of B cells (Shachar and Flavell, 
1996), the B cell maturation in SPPL2a/ CD74/ was not 
completely restored to the wild-type situation, but merely to 
that of CD74/ mice, which was considerably ameliorated 
compared with SPPL2a/ mice (Fig. 6, A–E, and Table 4). In 
agreement, mean size and abundance of Peyer’s patches were 
also significantly recovered in SPPL2a/ CD74/ mice 
(Fig. 6 F), and basal immunoglobulin levels, which were dras-
tically reduced in SPPL2a/ mice, were significantly higher 
in SPPL2a-CD74 double-deficient mice and comparable to 
those of CD74-deficient and wild-type mice (Fig. 6 G).
We further assessed the functional competence of B cells 
by analyzing the antibody response to the T cell–independent 
and –dependent antigens TNP-Ficoll (Fig. 6 H) and TNP-
KLH (Fig. 6 I). In SPPL2a/ mice, antigen administration 
elicited only a marginal antibody response, as described above. 
described changes on the cellular level, as well as impaired 
maturation of SPPL2a/ B cells, additional genetic ablation 
of CD74 in the SPPL2a-deficient mice should preclude NTF 
accumulation and result in a significant alleviation of the 
phenotype. We tested this by generating SPPL2a-CD74 double-
deficient mice. On the level of ultrastructure, SPPL2a/ 
CD74/ splenic IgM+ B cells were indistinguishable from 
corresponding wild-type and CD74/ cells (Fig. 5 A), as 
demonstrated by the mean number of vacuoles per cell 
(Fig. 5 B). This provides clear evidence that the undegraded 
CD74 NTF is responsible for the structural changes of endo-
somal compartments and the perturbation of membrane traf-
ficking. Furthermore, the reduced surface expression of the 
BAFF-R and the attenuated BCR-induced Ca2+ flux that has 
been observed in SPPL2a/ T1 B cells were also completely 
restored to the level of wild-type cells in SPPL2a/ CD74/ 
T1 B cells (Fig. 5, C and D), and should therefore be regarded 
as secondary events caused by the NTF accumulation.
B cell maturation and survival is significantly restored  
in SPPL2a/ CD74/ mice
We evaluated whether the recovery of cellular signaling in 
SPPL2a/ CD74/ B cells was reflected in enhanced B cell 
survival and improved function. SPPL2a/ CD74/ mice 
Figure 5. Ablation of CD74 restores 
morphological changes and cellular sig-
naling in SPPL2a/ B cells. (A) Representa-
tive cross sections of splenic IgM+ wild-type, 
SPPL2a/, CD74/, and SPPL2a/ CD74/ 
B cells. Bars, 1 µm. (B) Quantification (mean 
number ± SD) of endosomal vacuoles (diam  
≥250 nm) per cellular profile in splenic IgM+  
B cells from wild-type, SPPL2a/, CD74/, 
and SPPL2a/ CD74/ mice (n = 3–6 mice 
per genotype, quantification based on 50 cells 
per specimen). ***, P < 0.001, one-way ANOVA 
with Bonferroni post-hoc testing. (C) Spleno-
cytes from SPPL2a/, CD74/, SPPL2a/ 
CD74/, and wild-type mice were stained for 
B220, CD21, and CD24 and loaded with the 
ratiometric Ca2+-sensitive fluorophore Indo-
1-AM. In transitional stage T1 B cells (B220+ 
CD21low CD24high), the basal Ca2+ flux was 
monitored for 30 s before cells were stimu-
lated with goat anti–mouse IgM F(ab’)2 frag-
ments and Ca2+ flux was recorded for 5 min in 
the absence of extracellular Ca2+, and for an 
additional 5 min in the presence of 1 mM 
extracellular CaCl2. Data are representative of 
three experiments. (D) BAFF-R surface expres-
sion was determined on T1 B cells (B220+ 
CD21low CD24high) of SPPL2a/, CD74/, 
SPPL2a/ CD74/, and wild-type mice by 
co-staining isolated splenic B220+ cells for 
CD21, CD24, and BAFF-R. Data shown are repre-
sentative of three independent experiments.
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(Shachar and Flavell, 1996), which is reflected in the observa-
tion that for most subclasses, the hapten-specific immuno-
globulin levels detected in SPPL2a/ CD74/ mice were 
still significantly lower than those in wild-type mice. In con-
clusion, these findings indicate that not only B cell survival 
but also B cell function is noticeably improved by deletion of 
CD74 in SPPL2a/ mice.
In contrast, detectable amounts of hapten-specific IgM, 
IgG1, IgG2b, and IgG3 were produced by SPPL2a/ CD74/ 
mice. In the case of TNP-Ficoll, levels of TNP-specific IgM 
generated by SPPL2a-CD74 double-deficient mice were sig-
nificantly increased as compared with SPPL2a-deficient 
mice. CD74-deficient mice were reported before to exhibit im-
paired T cell–independent and –dependent antibody responses 
Figure 6. Recovery of B cell development 
and function by CD74 ablation identifies 
the accumulating NTF as the primary 
cause of B cell impairment in SPPL2a/ 
mice. (A and B) The frequency of B cells 
(B220+, % of PI cells) in BM, spleen, blood, 
LNs, and the peritoneal cavity (PC) of wild-
type, SPPL2a/, CD74/, and SPPL2a/ 
CD74/ mice was determined by flow cy-
tometry. Mean ± SD; n = 6 (BM, LN, and PC) 
or n = 12 (spleen). (C–E) Splenic B cell sub-
populations (Total B220+, transitional stage 
T1, transitional T2, and mature B cells) were 
determined in wild-type, SPPL2a/, CD74/, 
and SPPL2a/ CD74/ mice based on B220, 
CD21, and CD24 staining, and are depicted as 
the percentage of living cells (PI; C and D) or 
as absolute cell number (E) shown here from 
1 representative of 12 experiments (C) or as 
mean ± SD (D and E) derived from n = 12 (D) 
or n = 6 (E) mice per genotype. Plots display 
B220+ cells (C), with numbers indicating the 
percentage of living cells of the respective 
populations. (F) Number per animal and mean 
diameter of Peyer’s patches were determined 
in wild-type, SPPL2a/, CD74/, and  
SPPL2a/ CD74/ mice. Mean ± SD; n = 6. 
(G) Basal plasma immunoglobulin concentra-
tions of SPPL2a/ CD74/ mice (mean ± 
SD; n = 6). (H and I) Wild-type (wt), SPPL2a/, 
CD74/ and SPPL2a/ CD74/ mice were 
immunized with the T cell–independent or  
–dependent antigens TNP-Ficoll (H) or TNP-KLH 
(I), respectively. Hapten-specific immuno-
globulin levels were determined 14 d after 
antigen application (H and I). For TNP-KLH (I) 
a second dose of antigen was administered at 
day 14, and additional serum samples were 
obtained at day 28. Mean ± SD; n = 5. ***, P < 
0.001; **, P < 0.01; *, P < 0.05. One-way 
ANOVA with Bonferroni post-hoc testing was 
performed, and significance of wild-type ver-
sus SPPL2a/, wild-type versus SPPL2a/ 
CD74/, SPPL2a/ versus SPPL2a/ CD74/, 
and CD74/ versus SPPL2a/ CD74/ mice 
is depicted.
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of CD74 NTF produced by the removal of the luminal do-
main and the CLIP segment and to avoid an accumulation of 
this fragment. Apparently, this function of SPPL2a cannot be 
substituted by the multivesicular body pathway or other 
I-CLIPs of the SPPL family. In light of the severe phenotype 
caused by the NTF accumulation potential, minor contribu-
tions of reduced signaling by the absence of CD74 RIP 
cleavage products (Matza et al., 2002a,b) to the phenotype of 
SPPL2a/ mice may be masked. Therefore, our findings do 
not necessarily contradict the previously suggested model of 
signal transduction by the CD74 ICD, as discussed in this 
issue of the JEM by Beisner et al. and Bergmann et al. It is 
conceivable that this mechanism accounts for the residual 
phenotype of the SPPL2a-CD74 double-deficient mice that 
perfectly mirrors that of CD74-deficient mice.
Multiple studies have revealed possible functions of CD74 
for the regulation of endocytic trafficking (Lagaudrière-
Gesbert et al., 2002; Nordeng et al., 2002; Gregers et al., 2003; 
Landsverk et al., 2009, 2011). In overexpression systems, 
CD74 was shown to induce formation of giant endosome-
derived vacuoles by promoting endosomal fusion, to delay 
maturation of endosomal compartments, and to modulate the 
processing and degradation of internalized antigens. The 
cytoplasmic N-terminal tail has been identified as the critical 
DISCUSSION
By identifying SPPL2a as the postulated and long sought 
intramembrane protease of CD74, we provide the missing 
mechanistic link for a process that is essential for B cell devel-
opment, as indicated by previous studies (Matza et al., 
2002a,b). Moreover, we have discovered the first in vivo–
validated substrate of SPPL2a and present novel insights into 
the function of this poorly characterized protease. We con-
clude that RIP of CD74 by SPPL2a is indispensable for B cell 
development based on the distinct and severe B cell matura-
tion defect in SPPL2a-deficient mice. The significant recov-
ery of this phenotype achieved by additional ablation of 
CD74 clearly demonstrates that the phenotype can be mainly at-
tributed to failed proteolysis of CD74 in the absence of SPPL2a. 
Contributions by other, possibly yet to be discovered sub-
strates or nonproteolytic functions of SPPL2a, may not be 
fully excluded, but seem to be of minor importance in view 
of these findings. The alleviated phenotype of SPPL2a/ 
CD74/ mice strongly suggests that the accumulation of the 
uncleaved CD74 NTF, and not the absence of any cleavage 
products, is the driving force of the B cell phenotype in 
SPPL2a/ mice. Therefore, we would like to propose a 
novel perspective. According to our data, the major role of 
CD74 RIP mediated by SPPL2a is to tightly control the level 
Table 4. B cell deficiency of SPPL2a/ mice was recovered to a significant degree in SPPL2a/ CD74/ mice
Cell type  Wild-type  SPPL2a/  CD74/  SPPL2a/ CD74/  P-value
  Mean  SD  Mean  SD  Mean  SD  Mean  SD  SPPL2a// 
do-ko
BM (% of viable cells)
 B cells B220+ 24.0 7.7 22.8 5.9 17.4 3.5 16.7 6.3 ≥0.05
 Pro– /pre–B cells B220+ IgM− 13.8 4.4 16.6 3.1 12.2 1.7 10.8 3.7 <0.05*
 Immature B cells B220+ IgM+ 3.7 1.1 3.8 2.1 3.2 1.3 2.9 1.3 ≥0.05
 Recirculating B cells B220high 4.7 3.3 0.8 0.8 0.8 0.6 1.6 1.1 ≥0.05
Spleen (% of viable cells)
 B cells B220+ 53.4 6.4 25.0 6.6 39.3 7.8 35.3 10.1 <0.05*
 T1 transitional B220+ CD21low CD24high 9.0 2.2 14.3 3.9 11.1 3.3 9.5 4.4 <0.05*
 T2 transitional B220+ CD21high CD24high 7.2 1.9 0.3 0.5 10.8 4.3 9.5 3.6 <0.001***
 Mature B cells B220+ CD21low CD24low 32.0 4.0 4.1 2.0 11.3 2.0 10.4 3.0 <0.001***
Spleen (x106 splenocytes)
 B cells B220+ 39.7 7.4 6.8 3.1 12.3 4.0 9.2 5.1 ≥0.05
 T1 transitional B220+ CD21low CD24high 6.8 1.7 3.8 1.8 3.4 1.5 2.3 1.5 ≥0.05
 T2 transitional B220+ CD21high CD24high 5.5 1.9 0.03 0.03 3.7 1.1 2.6 1.3 <0.05*
 Mature B cells B220+ CD21low CD24low 23.6 4.4 1.2 0.7 3.2 1.3 2.8 1.7 ≥0.05
LNs (% of viable cells)
 B cells B220+ 28.1 4.8 3.1 1.3 12.6 3.0 12.4 2.7 <0.001***
Peritoneal cells (% of viable cells)
 B cells B220+ 40.1 12.8 8.5 5.6 34.5 7.0 38.0 9.4 <0.001***
 B1 B220neg/low CD19high 24.5 8.7 7.7 5.5 27.2 8.8 31.8 9.1 <0.001***
 B2 B220high CD19+/low 15.1 5.0 0.8 0.4 7.3 2.4 7.4 2.6 <0.01**
B cell subsets were analyzed by flow cytometry in BM, spleen, LNs, and peritoneal lavage of wild-type, SPPL2a/, CD74/, and SPPL2a/ CD74/ (do-ko) mice. Proportions 
of cell populations are shown as percentage of viable cells (PI) or absolute cell numbers, respectively. Results represent mean ± SD from n = 6 mice per genotype (BM, 
absolute number of splenocytes, LNs, and peritoneal cells) or n = 12 mice (spleen, % of viable cells), respectively. Data were analyzed by one-way ANOVA with Bonferroni 
post-hoc testing. ***, P < 0.001; **, P < 0.01; *, P < 0.05.  o
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is also attenuated in SPPL2a/ B cells, a pathway that has 
been shown to control cell fate decisions in B cells (Engelke 
et al., 2007). Hence, the altered Ca2+ signals might account, at 
least in part, for the observed B cell maturation arrest.
The CD74 NTF, that is observed in SPPL2a/ B cells, 
has been proteolytically separated from the CLIP segment by 
cathepsin S (Nakagawa et al., 1999). Because CLIP represents 
the major binding site between CD74 and MHCII, no signif-
icant direct effects of this NTF on MHCII trafficking and 
peptide loading would be expected in contrast to those re-
ported in the absence of cathepsin S (Driessen et al., 1999). 
Therefore, we were intrigued to detect a considerable increase 
of surface and, even more pronounced, total MHCII levels in 
SPPL2a/ B cells. Apart from the CLIP segment, additional 
interaction sites between CD74 and MHCII were demon-
strated to involve the transmembrane segment of CD74 
(Castellino et al., 2001), which would be preserved in the ac-
cumulating NTF. Based on these findings, weak interactions 
between the CD74 NTF and MHCII may take place in 
SPPL2a/ B cells. These intereactions may, in sum, exert 
biologically relevant effects on MHCII, considering the massive 
amounts of accumulating NTF in comparison to CD74 levels 
in wild-type B cells. Trafficking and turnover of MHCII was 
shown to be controlled by ubiquitination by the ubiquitin 
ligase MARCH I in DCs, as well as in B cells (Ma et al., 2012; 
De Gassart et al., 2008). In DCs, degradation of CD74 was 
found to be a prerequisite for MHCII ubiquitination (van 
Niel et al., 2006). Thus, it may be speculated that the CD74 
NTF accumulating in SPPL2a-deficient B cells interferes 
with MHCII ubiquitination and, consecutively, its turnover 
accounting for the increased levels of MHCII in these cells.
Different explanations have been suggested for the afore-
mentioned B cell deficiency and maturation block observed in 
CD74-deficient mice. This phenotype was found to be com-
pletely resolved when these mice were bred into an MHCII-
deficient background (Maehr et al., 2004). This study clearly 
demonstrated that both CD74 and MHCII are dispensable for 
B cell maturation and that MHCII plays a decisive role in the 
emergence of B cell developmental arrest in CD74/ mice. 
Similar to ablation of CD74, the knockout of individual chains 
of MHCII was reported to lead to B cell deficiency (Labrecque 
et al., 1999), indicating that dysregulations of MHCII homeo-
stasis may be capable of negatively affecting B cell survival. 
Thus, further studies will be required to analyze the mecha-
nisms, including the disturbed endosomal trafficking induced 
by CD74 NTF that lead to increased MHCII levels in 
SPPL2a/ B cells and the putative consequences this may 
have on cellular homeostasis and B cell maturation. These as-
pects may be dissected in the future by studying the effects of 
MHCII ablation on the B cell phenotypes of SPPL2a/ and 
SPPL2a/ CD74/ mice, similar to studies carried out on 
CD74/ mice (Maehr et al., 2004).
Because B cells are exceptionally dependent on SPPL2a 
and SPPL2a/ mice do not appear to be significantly com-
promised despite the ubiquitous tissue expression of this 
enzyme in wild-type mice (Friedmann et al., 2004), SPPL2a 
determinant of CD74 mediating these effects (Nordeng et al., 
2002; Gregers et al., 2003). Interaction of this domain with 
the uncoating ATPase Hsc70 has been suggested to represent 
the molecular mechanism (Lagaudrière-Gesbert et al., 2002). 
The structural alterations of the endocytic system observed 
upon CD74 NTF accumulation in SPPL2a/ B cells agree 
well with these studies and provide in vivo confirmation 
for the potential of CD74 to modulate membrane traffic 
in the endocytic system as reported already for cathepsin 
S–deficient cells (Boes et al., 2005).
The phenotype of SPPL2a/ mice shows intriguing 
similarity to that of mice deficient either for the cytokine 
BAFF (Schiemann et al., 2001) or its receptor, BAFF-R 
(Shulga-Morskaya et al., 2004), regarding the loss of mature 
B cells and the developmental arrest at the T1 stage. Conspicu-
ously, SPPL2a-deficient T1 B cells show a reduced level of 
BAFF-R surface expression as compared with corresponding 
wild-type cells. Apparently, this was secondary to the accumu-
lation of CD74 NTF as it was reversed in SPPL2a/ 
CD74/ B cells. It is tempting to speculate that the impaired 
transduction of BAFF-mediated survival signals due to re-
duced receptor levels may represent an important part of 
the mechanism linking accumulation of uncleaved CD74 
NTF with compromised B cell maturation. However, the 
functional deficits of residual B cells in BAFF-R/ mice 
completely lacking the BAFF-R seem to be slightly less 
pronounced than in SPPL2a/ mice, which is reflected in 
preserved antibody responses to the T cellindependent 
antigen TNP-Ficoll (Shulga-Morskaya et al., 2004). It may be 
interesting to analyze if changes of surface expression on 
SPPL2a/ B cells are also detectable for other receptors of 
BAFF-like TACI and BCMA (Rickert et al., 2011). TACI/ 
mice do not show a depletion of mature B cells, B1 and mar-
ginal zone B cells, but were reported to demonstrate impaired 
responses to T cell–independent antigens caused by a reduced 
responsiveness of these cells (von Bülow et al., 2001; Yan et al., 
2001). Therefore, it is conceivable that the severe functional 
deficits of the remaining B cells in SPPL2a/ mice may be 
related to additional changes in other BAFF receptors, like 
TACI, and associated downstream signaling pathways. How-
ever, we have determined BAFF serum levels in SPPL2a/ 
mice in comparison to wild-type mice and found them to be 
significantly increased (97.5 ± 39.6 ng/ml vs. 4.2 ± 4.4 ng/ml; 
P < 0.001). Elevated BAFF levels as a consequence of B cell 
deficiency have been reported before (Kreuzaler et al., 2012), 
and therefore presumably reflect the diminished B cell com-
partment in SPPL2a/ mice. Apparently, BAFF levels in-
creased by 20-fold are not able to overcome the B cell 
maturation defect, rendering it unlikely that reduced BAFF-R 
surface expression as well as putative changes to additional 
BAFF-Rs, like TACI and BCMA (not analyzed), are exclu-
sively responsible for the severe phenotype.
Therefore, additional effects might be exerted by the CD74 
NTF accumulation and contribute to the described pheno-
type of SPPL2a-deficient B cells. This interpretation is sup-
ported by our finding that BCR-induced Ca2+ mobilization 
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For initial phenotypic analyses of SPPL2a-deficient mice (datasets pre-
sented in Figs. 2 and 3 and Tables 1–3) animals on a mixed genetic back-
ground (C57BL/6N/129/Sv) were used. Subsequently, SPPL2a/ mice 
were backcrossed for 10 generations on a C57BL/6N Crl background and 
bred with CD74/ mice (C57BL/6 background) for generation of SPPL2a-
CD74 double-deficient mice (datasets depicted in Figs. 5 and 6 and Table 4). 
Animal experimentation was performed in agreement with the guidelines of 
the University of Hamburg (acceptance no. 78/07) and the University of 
Kiel (acceptance no. V 312–72241.121-3 [22–2/10]) for use of animals and 
their care.
cDNA constructs and siRNA. Murine CD74 p41 cDNA (clone 
IRAVp968E041D) was obtained from ImaGenes. Based on this template, 
two epitope-tagged expression constructs of the shorter and more abundant 
p31 isoform (HA-mCD74p31-V5 and mCD74p31-HA) were generated by 
overlap-extension PCR. For this purpose, HA-mCD74-BamHI-Fw (5-GAT-
CGGATCCACGCCACCATGTACCCATACGACGTCCCAGAC-
TACGCTGATGACCAACGCGACCTCA-3) and mCD74-V5-XhoI-
Rv (5-GATCCTCGAGTCACGTAGAATCGAGACCGAGGAGAGGG-
TTAGGGATAGGCTTACCCAGGGTGACTTGACCCAGTTC-3), or 
mCD74-BamHI-Fw (5-GATCGGATCCACGCCACCATGGATGAC-
CAACGCGACCT-3) and mCD74-HA-XhoI-Rv (5-GATCCTCGAG-
TCAAGCGTAGTCTGGGACGTCGTATGGGTACAGGGTGACTT-
GACCCAGTTC-3), were used as flanking primers and mCD74-p31-Fw 
(5-AGCCCACCGAGGCTCCACCTAAAGAGCCACTGGACATGGA-
AGACC-3) in conjunction with mCD74-p31-Rv (5-GGTCTTCCA-
TGTCCAGTGGCTCTTTAGGTGGAGCCTCGGTGGGCT-3) were 
used as internal primers, respectively. PCR products were subcloned into 
pcDNA3.1/Hygro+ (Invitrogen) after restriction digestion with BamHI and 
XhoI. For the generation of stably expressing HEK293 Flp-In cells (Invitrogen), 
the insert HA-mCD74p31-V5 was excised from the respective pcDNA3.1/
Hygro+ construct and subcloned into pcDNA5/FRT (Invitrogen).
Cloning of an expression construct of murine SPPL2a with a C-terminally 
appended myc epitope has been described previously (Behnke et al., 2011). 
The active site mutant D416A was generated by overlap-extension PCR 
using mSPPL2a-D416A-Fw (5-GGTTTCGGAGCAATCATTGTA-
CCAGGCCTGTTG-3) and mSPPL2a-D416A-Rv (5-TACAATGAT-
TGCTCCGAAACCCAATACTGAAAC-3) as internal primers and 
mSPPL2a-HindIII-Fw (5-CTGAAAGCTTGCCACCATGGGGCTG-
CTGCACTCG-3) and mSPPL2a-Myc-XhoI-Rv (5-GTTACTCGAG-
TTACAGATCCTCTTCTGAGATGAGTTTTTGTTCCTGTTGTA-
CAATCTGCTCATCAGTCGTC-3) as flanking primers, respectively.
Transient down-regulation of human SPPL2a in HEK Flip-In cells was 
performed with Stealth Select RNAi (Invitrogen) siRNA: HSS131389 
(5-GGGCAACCUGCUCUCCUCUAUUUAG-3), HSS131390 (5-GGA-
CCAUUUGGAUUGUGCAACAAAU-3), and HSS131391 (5-GAUAU-
UCCUCCUGUUGGCAUAAAGA-3 ). As a control, recommended 
nontargeting control siRNAs from the same supplier were used.
Cell culture and transfection. HeLa, HEK293, and HEK293 Flp-In 
(Invitrogen) cells were maintained in DMEM (PAA) supplemented with 10% 
(vol/vol) FBS (PAA), 100 U/ml penicillin (PAA), and 100 µg/ml strepto-
mycin (PAA). All cell lines were transiently transfected at semiconfluence 
using Turbofect (Fermentas) corresponding to manufacturer’s instructions 
with 2.5 µg DNA per 10-cm culture dish. To reduce cytotoxicity, the cul-
ture medium was replaced by fresh medium 6 h after transfection.
HEK293 cells stably expressing HA-mCD74p31-V5 were generated 
based on HEK293 Flp-In cells (Invitrogen). Before transfection, HEK293 
Flp-In were propagated in the presence of 100 µg/ml Zeocin (Invitrogen). 
Cells were co-transfected with HA-mCD74p31-V5 in pcDNA5/FRT 
(Invitrogen) and pOG44 (Invitrogen) according to manufacturer’s instructions. 
Selection was initiated with 200 µg/ml Hygromycin (PAA) 48 h after trans-
fection. Hygromycin-resistant cells were kept under selection conditions and 
maintained as a batch without subcloning. Expression of mCD74p31 was 
validated by Western blotting and indirect immunofluorescence.
may represent a novel pharmacological target to selectively 
interfere with B cell–driven immune responses, as all mature 
B cell subsets are similarly affected by absence of SPPL2a. 
B cells play a well-documented role in the pathogenesis of 
several autoimmune disorders, such as rheumatoid arthritis, 
Sjögren’s syndrome, multiple sclerosis, systemic lupus erythe-
matosus (SLE), myasthenia gravis, and pemphigus vulgaris 
(Viau and Zouali, 2005; Townsend et al., 2010). Thus, thera-
peutic strategies targeting B cells have been developed and 
reviewed over the past few years, the majority of them based 
on antibodies, e.g., rituximab (Dörner et al., 2009). We sug-
gest that pharmacological inhibition of SPPL2a activity should 
be evaluated as a potential therapeutic strategy for depleting 
B cells and modulating humoral immune responses to treat 
autoimmune disorders. Based on available compounds inhib-
iting the mechanistically related -secretase, the development 
of potent and specific small-molecule SPPL2a inhibitors may 
be an attainable goal.
MATERIALS AND METHODS
Experimental animals. The strategy for targeting of the murine SPPL2a 
gene by insertion of a neomycin-cassette in exon 2 is illustrated in Fig. 2 A. 
For generation of the targeting construct, a 5.1-kB fragment surrounding 
exon 2 of murine SPPL2a (2.3-kb 5-homology arm and 2.8-kb 3-homol-
ogy arm) was amplified from genomic DNA of 129SVJ mice and sub-
cloned in pJET1/blunt (Fermentas). The neomycin expression cassette 
from pMC1neo (Stratagene) was inserted into exon 2 by overlap-extension 
PCR so that concomitantly 57 bp of exon 2 sequence were deleted. The fu-
sion PCR product was subcloned into pJET1/blunt. The targeting vector 
was linearized with XhoI and electroporated into the embryonic stem (ES) 
cell line R1 (Nagy et al., 1993). G418-resistant colonies were initially screened 
by PCR for homologous recombination. Positive clones were confirmed by 
Southern blot analysis after restriction digest of genomic DNA with NdeI. 
A probe comprising 454 bp of the 5 upstream region was generated by 
PCR from genomic DNA. The targeted ES cells were injected into blasto-
cysts of C57BL/6 mice. Chimeric male offspring was mated with C57BL/6N 
Crl females.
Mice were genotyped by PCR using SPPL2a-specific primers (for-
ward, 5-AAACTCATTGAAGGACTTGCTC-3; reverse, 5-TTTCT-
AGGGAACTTGGAAGTC-3) amplifying PCR products of 242 and 
1,323 bp from the wild-type and targeted locus, respectively. In addition, 
a PCR specifically detecting the neomycin expression cassette (forward, 
5-GTTGTCACTGAAGCGGGAAGGGACTGGCTG-3; reverse, 5-GCG-
AACAGTTCGGCTGGCGCGAGCCCCTGA-3) with a product of 280 bp 
was performed (Fig. 2 A). Absence of SPPL2a wild-type transcript was con-
firmed by RT-PCR (Fig. 2 A). Total RNA was isolated from tissues or murine 
embryonic fibroblasts with the NucleoSpin RNA II kit (Macherey-Nagel). 
Reverse transcription was conducted using the RevertAid First Strand 
cDNA Synthesis kit (Fermentas) and random hexamer primers. Primers an-
nealing in exons 1 and 3 of the SPPL2a ORF (forward, 5-CACTCGCTG-
CACGCTCCC-3; reverse, 5-CACCTTCCTGTGCAATTCTGGCT-3) 
were used to amplify a 342-bp fragment of the SPPL2a wild-type transcript 
from the cDNA. In parallel, appropriate primers for a fragment of -actin 
(forward, 5-GTTACAACTGGGACGACATGG-3; reverse, 5-GATGGC-
TACGTACATGGCTG-3) were used as a control.
CD74-deficient mice (B6.129S6-Cd74tm1Liz/J) have been described 
previously (Bikoff et al., 1993) and were obtained from The Jackson Labora-
tory for breeding with SPPL2a/ mice to generate SPPL2a-CD74 double-
deficient animals. Rag2/ cc/ mice (Goldman et al., 1998) were obtained 
from Taconic. All experiments were performed with littermates and/or ap-
propriate controls matched for sex and age.
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from eBioscience in MACS buffer (PBS supplemented with 2 mM EDTA 
and 0.5% [wt/vol] BSA). To detect total MHCII, anti-MHCII was omitted at 
this stage, and cells were fixed with 2% PFA in PBS, permeabilized with 
0.1% (wt/vol) saponin in PBS containing 5% (vol/vol) FBS and stained with 
anti-MHCII (M5/114.15.2) for 30 min at 4°C. In both cases, lysis of eryth-
rocytes was performed by incubation in FACS Lysing Solution (BD) for 
10 min at room temperature before flow cytometric analysis.
Flow cytometry was performed using a LSRII, FACSCanto, or FACS-
Calibur flow cytometer (BD). Data were analyzed with FACSDiva, Cell-
Quest II (BD) or FlowJo (Tree Star) software.
Isolation of B cells. For generation of a single cell suspension murine 
spleens were cut into pieces and passed through a 100-µm cell strainer sus-
pended in MACS buffer (PBS supplemented with 2 mM EDTA and 0.5% 
[wt/vol] BSA). IgM+ B cells were obtained by positive selection using anti–
mouse IgM MicroBeads and LS columns of the MACS cell separation sys-
tem (Miltenyi Biotec) according to the manufacturer’s instructions. B cell 
purity was found to be between 80 and 90% as determined by flow cytomet-
ric analysis using anti-CD45R. Similarly, for immunofluorescent staining of 
B cells, total splenic B cells were recovered from splenocytes using the Pan 
B cell isolation kit (Miltenyi Biotec) and LD depletion columns. Splenic B cell 
subpopulations (T1, T2, and Mature B cells) for analysis of SPPL2a expres-
sion by Western blotting were obtained by staining B220+ MACS-isolated 
splenic B cells with anti-B220, anti-CD21, and anti CD-24 followed by 
fluorescence-activated cell sorting using a FACSAria I (BD).
Histology and immunohistochemistry. Mice were anesthetized by i.p. 
injection of xylazine/ketamine and perfused with 4% (wt/vol) PFA in PBS. 
Organs were post-fixed in 4% (wt/vol) PFA overnight. Spleens, LNs, or 
Peyer’s patches were either embedded into Jung Tissue Freezing Medium 
(Leica) or paraffin and sectioned at 5 µm. Paraffin sections were stained with 
hematoxylin and eosin according to standard protocols. Cryostat sections 
were boiled for 5 min in 10 mM citrate buffer, pH 6.0, for epitope retrieval 
and stained with anti-CD45R (RA3-6B2; Immunotools) and anti-CD3 
(C7930; Sigma-Aldrich). Alkaline phosphatase labeled anti–rabbit IgG 
(C7930; Sigma-Aldrich) was used to visualize CD3 antibody binding by 
NBT-BCIP staining (Sigma-Aldrich). Sensitivity of anti-CD45R staining 
was enhanced by incubation with biotinylated anti–rat IgG (Vector Labora-
tories), followed by addition of Streptavidin-HRP (Vectastain ABC kit; 
Vector Laboratories). HRP activity was visualized by peroxidase substrate kit 
DAB (Vector Laboratories). Sections were embedded in 17% Mowiol 4–88 
(EMD Millipore), 33% glycerol, and 20 mg/ml DABCO (1,4-diaza-bicy-
clo-[2,2,2]-octane) in PBS and viewed with an Olympus BX50 microscope 
(Olympus) equipped with U Plan Fl 4× (N.A. 0.13) or 10× (N.A. 0.30) ob-
jectives (Olympus). Images were acquired with an Olympus UC30 digital 
color camera and Olympus Soft Imaging solutions software and further pro-
cessed using Adobe Photoshop.
Indirect immunofluorescence. Coverslips were coated in 100 µg/ml 
poly-L-lysine (Sigma-Aldrich) overnight and washed twice with water for 
1 h before use. Total splenic B cells isolated by negative depletion using the 
MACS-system were cultured on coated coverslips in RPMI-1640 (PAA; 
Cölbe) supplemented with 2 mM l-glutamine, 100 U/ml penicillin (PAA), 
and 100 µg/ml streptomycin (PAA) for 1.5 h at 37°C. Cells were fixed in 4% 
(wt/vol) PFA in PBS for 20 min at room temperature. Immunocytochemi-
cal stainings were performed as described previously (Savalas et al., 2011) 
with anti-CD74 (In-1; BD) or a polyclonal antiserum raised against the 
N terminus of CD74 (Barois et al., 1997) provided by N. Barois (Institut 
Pasteur de Lille, Lille, France) and W. Stoorvogel (Faculty of Veterinary 
Medicine, Utrecht University, Utrecht, Netherlands) and anti-EEA1 (clone 
C45B10; Cell Signaling Technology) or anti-LAMP1 (1D4B; Developmen-
tal Studies Hybridoma Bank) as primary and Alexa Fluor 488– or 594–
conjugated goat anti–rat IgG or goat anti–rabbit IgG as secondary antibodies 
(MoBiTec), respectively. Coverslips were mounted on glass slides in a me-
dium containing 17% Mowiol 4–88 (EMD Millipore), 33% glycerol, and 
A pool of three different siRNAs directed against human SPPL2a, as 
well as of three nontargeting control siRNAs, were transfected into HEK293 
Flp-In cells stably expressing HA-mCD74p31-V5 with INTERFERin 
(Polyplus transfection) according to the manufacturer’s recommendations, 
with a final concentration of 50 nM siRNA in the culture medium.
For inhibition of proteases, the following reagents were used at the con-
centration indicated in Fig. 1 B: (Z-LL)2-ketone (Peptanova), leupeptin 
(Roth), inhibitor X (EMD Millipore), and NH4Cl (Merck).
Protein extraction and immunoblotting. Cultured cells were harvested 
by scraping into PBS and cells were sedimented at 1,000 g for 5 min. Pelleted 
cells were extracted in lysis buffer (50 mM Tris/HCl, pH 7.4, 150 mM 
NaCl, 1.0% [vol/vol] Triton X-100, 0.1% [wt/vol] SDS, and 4 mM EDTA) 
supplemented with protease inhibitors as described previously (Schröder et al., 
2010). Samples were sonicated (level 4 for 20 s) using a Branson Sonifier 
450 (Emerson Industrial Automation) at 4°C and incubated on ice for 1 h. 
Lysates were cleared by centrifugation (15,000 g for 10 min) and the protein 
concentration was determined with a bicinchoninic acid protein assay kit 
(Thermo Fisher Scientific).
SDS/PAGE (Laemmli, 1970), semidry transfer onto nitrocellulose and 
immunodetection were performed as described previously (Schröder et al., 
2010). For the detection of SPPL2a, the boiling step was omitted and sam-
ples were incubated for 5 min at 56°C instead. To improve higher resolution 
of CD74 NTFs, Tricine-SDS-PAGE (Schägger, 2006) was used along with 
a separating gel with T = 16% and C = 6% supplemented with 6 M urea. 
Overnight semidry transfer to nitrocellulose was performed as previously 
described (Schägger, 2006).
For protein detection on Western Blots, the primary antibodies anti-
CD74 (In-1; BD), anti-mSPPL2a (Behnke et al., 2011), a monoclonal anti–
human SPPL2a (KLH-6E9-11; provided by R. Fluhrer and E. Kremmer, 
DZNE, German Center for Neurodegenerative Diseases, Munich, Ger-
many), anti-actin (Sigma-Aldrich), anti-tubulin (Developmental Studies 
Hybridoma Bank, Iowa city, IA), anti–MHC-II (M5/114.15.2; eBioscience), 
and anti-HA (Roche) were used. The HRP-labeled secondary antibodies 
goat anti–rabbit, sheep anti–mouse, and goat anti–rat (Dianova) were used 
followed by detection with Amersham ECL Advance Western Blotting De-
tection Reagent (GE Healthcare).
Flow cytometric analysis. To obtain single-cell suspensions, LNs and 
spleens were cut into pieces and passed through a 100-µm cell strainer sus-
pended in FACS buffer (PBS containing 2% [vol/vol] FBS, 0.1% [wt/vol] 
NaN3, and 2 mM EDTA, pH 7.4). Red BM was isolated from femur and 
tibia of hind limbs by flushing the bones with FACS buffer and dissociated 
by a 100-µm cell strainer. Peritoneal cells were obtained by injecting 7 ml 
FACS buffer into the murine peritoneal cavity, and cells were dispensed by 
gentle massage and collected afterward. Lysis of erythrocytes was performed 
by incubation in 155 mM NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA for 
10 min at room temperature.
Cell suspensions were stained for 30 min at 4°C with the following 
FITC-, PE-, PE/Cy5-, PE/Cy7-, or APC-conjugated murine antibodies: 
anti-CD3 (145-2C11), anti-CD4 (GK1.5), anti-CD11c (N418), anti-
CD21/CD35 (8D9), anti-CD268 (BAFF-R, 7H22-E16), and anti-CD45R 
(RA3-6B2; all from eBioscience); anti-CD4 (PJP6), anti-CD8a (YTS 169.4), 
and anti-CD19 (PeCa1; all from Immunotools); anti-CD11b (M1/70), anti-
CD21 (7G6), anti-CD43 (S7), anti-CD117 (Ckit, 2B8), anti-IgD (11-
26c.2a), anti-IgM (R6-60.2), anti-Gr-1 (RB6-8C5), and anti-TCRV5.1,5.2 
(MR9-4; all from BD); anti-CD3 (17A2), anti-CD4 (RM4-5), anti-CD8a 
(53–6.7), anti-CD23 (B3B4), anti-CD24 (M1/69), anti-CD49b (DX5), and 
anti–I-AB MHCII (AF6-120.1; all from BioLegend); anti-F4/80 (CI:A3-1; 
AbD Serotec); and anti-ST2 (DJ8; mdBiosciences). After washing, stained 
cells were resuspended in 0.5 µg/ml PI to stain dead cells (PI+).
For analysis of surface MHCII, single-cell suspensions from spleen were 
obtained as described above without performing lysis of erythrocytes. Cells 
were stained for 30 min at 4°C with anti-CD21/CD35 (8D9), anti-CD24 
(M1/69), and anti-CD45R (RA3-6B2), along with anti-MHCII (M5/114.15.2) 
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TNP-KLH in 100 µl PBS supplemented with 50% (vol/vol) incomplete 
Freund’s adjuvant (Sigma-Aldrich) was performed. At day 28, mice were 
sacrificed and the blood was analyzed.
For determination of TNP-specific antibodies, 96-well ELISA plates 
(Thermo Fisher Scientific) were coated with 10 µg/ml TNP-ovalbumin 
(Biosearch Technologies) in PBS at 4°C overnight, washed, and blocked with 
1% (wt/vol) casein in PBS. Different dilutions of serum were added to the 
plates and incubated for 2 h at room temperature. After washing, isotype 
specific HRP-conjugated goat anti–mouse immunoglobulin antibodies 
(5300–05; Southern Biotech) were added for 1 h at room temperature. BM 
Blue POD Substrate (Roche) was used for detection.
Analysis of B cell receptor signaling. For analysis of intracellular Ca2+ 
concentration, splenocytes were stained with anti–CD45R-PE-Cy7, anti–
CD21-FITC, and anti–CD24-PE (BD) and subsequently loaded for 25 min at 
30°C with 1 µM Indo-1-AM (Invitrogen) in RPMI medium containing 5% 
(vol/vol) FBS and 0.015% Pluronic F127 (Invitrogen) under mild agitation. 
Cells were diluted 1:1 with RPMI containing 10% (vol/vol) FBS and incu-
bated for 10 min 37°C before being washed with and resuspended in Kreb’s 
Ringer solution, composed of 10 mM Hepes, pH 7.0, 140 mM NaCl, 4 mM 
KCl, 1 mM MgCl2, 1 mM CaCl2, and 10 mM glucose plus 0.5 mM EGTA. 
After basal Ca2+ concentrations were monitored, cells were stimulated with 
10 µg/ml goat anti–mouse IgM immunoglobulin F(ab’)2 fragments from 
Jackson ImmunoResearch Laboratories. After 6 min, CaCl2 was added to achieve 
an extracellular Ca2+ concentration of 1 mM. The fluorescence ratio of Ca2+-
bound Indo-1 (405 nm) to Ca2+-unbound Indo-1 (530 nm) was monitored on 
an LSRII cytometer (BD) and data were processed with FlowJo (Tree Star).
BM transplantations. BM cell suspensions were isolated from SPPL2a+/+ 
and SPPL2a/ mice. 107 BM cells (containing on average <2% CD4+ and 
CD8+ T cells) were intravenously injected into irradiated (9 Gy) Rag2/ 
cc/ mice devoid of B, T, and NK cells. 6 wk after transplantation, periph-
eral blood was collected and analyzed by flow cytometry for reconstitution 
with B cells, T lymphocytes, and NK cells. 10 wk after transplantation, the 
animals were sacrificed to analyze spleens, BM, and thymi.
Statistics. Data are shown as means ± SD. For statistical analyses, unpaired 
two-tailed Student’s t test or one-way ANOVA followed by Bonferroni 
post-hoc testing was used, as indicated. Significance levels of P < 0.05 (*), 
P < 0.01 (**), and P < 0.001 (***) were applied.
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